Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 187

Similar articles for PubMed (Select 21619515)

1.

6-oxopurine phosphoribosyltransferase: a target for the development of antimalarial drugs.

de Jersey J, Holý A, Hocková D, Naesens L, Keough DT, Guddat LW.

Curr Top Med Chem. 2011;11(16):2085-102. Review.

PMID:
21619515
2.

Synthesis of novel N-branched acyclic nucleoside phosphonates as potent and selective inhibitors of human, Plasmodium falciparum and Plasmodium vivax 6-oxopurine phosphoribosyltransferases.

Hocková D, Keough DT, Janeba Z, Wang TH, de Jersey J, Guddat LW.

J Med Chem. 2012 Jul 12;55(13):6209-23. doi: 10.1021/jm300662d. Epub 2012 Jun 22.

PMID:
22725979
3.

Synthesis of 9-phosphonoalkyl and 9-phosphonoalkoxyalkyl purines: evaluation of their ability to act as inhibitors of Plasmodium falciparum, Plasmodium vivax and human hypoxanthine-guanine-(xanthine) phosphoribosyltransferases.

Česnek M, Hocková D, Holý A, Dračínský M, Baszczyňski O, Jersey Jd, Keough DT, Guddat LW.

Bioorg Med Chem. 2012 Jan 15;20(2):1076-89. doi: 10.1016/j.bmc.2011.11.034. Epub 2011 Dec 1.

PMID:
22178188
4.

Plasmodium vivax hypoxanthine-guanine phosphoribosyltransferase: a target for anti-malarial chemotherapy.

Keough DT, Hocková D, Krecmerová M, Cesnek M, Holý A, Naesens L, Brereton IM, Winzor DJ, de Jersey J, Guddat LW.

Mol Biochem Parasitol. 2010 Oct;173(2):165-9. doi: 10.1016/j.molbiopara.2010.05.018. Epub 2010 Jun 1.

PMID:
20595032
5.

Synthesis of purine N9-[2-hydroxy-3-O-(phosphonomethoxy)propyl] derivatives and their side-chain modified analogs as potential antimalarial agents.

Krečmerová M, Dračínský M, Hocková D, Holý A, Keough DT, Guddat LW.

Bioorg Med Chem. 2012 Feb 1;20(3):1222-30. doi: 10.1016/j.bmc.2011.12.034. Epub 2011 Dec 30.

PMID:
22249123
6.

Plasmodium falciparum: new molecular targets with potential for antimalarial drug development.

Gardiner DL, Skinner-Adams TS, Brown CL, Andrews KT, Stack CM, McCarthy JS, Dalton JP, Trenholme KR.

Expert Rev Anti Infect Ther. 2009 Nov;7(9):1087-98. doi: 10.1586/eri.09.93. Review.

PMID:
19883329
7.

Molecular and biological aspects of antimalarial resistance in Plasmodium falciparum and Plasmodium vivax.

Bustamante C, Batista CN, Zalis M.

Curr Drug Targets. 2009 Mar;10(3):279-90. Review.

PMID:
19275564
8.

Aza-acyclic nucleoside phosphonates containing a second phosphonate group as inhibitors of the human, Plasmodium falciparum and vivax 6-oxopurine phosphoribosyltransferases and their prodrugs as antimalarial agents.

Keough DT, Hocková D, Janeba Z, Wang TH, Naesens L, Edstein MD, Chavchich M, Guddat LW.

J Med Chem. 2015 Jan 22;58(2):827-46. doi: 10.1021/jm501416t. Epub 2014 Dec 24.

PMID:
25494538
9.

Synthesis of branched 9-[2-(2-phosphonoethoxy)ethyl]purines as a new class of acyclic nucleoside phosphonates which inhibit Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase.

Hocková D, Holý A, Masojídková M, Keough DT, de Jersey J, Guddat LW.

Bioorg Med Chem. 2009 Sep 1;17(17):6218-32. doi: 10.1016/j.bmc.2009.07.044. Epub 2009 Jul 25.

PMID:
19666228
10.

Chemoresistance of Plasmodium falciparum and Plasmodium vivax parasites in Brazil: consequences on disease morbidity and control.

Gama BE, Lacerda MV, Daniel-Ribeiro CT, Ferreira-da-Cruz Mde F.

Mem Inst Oswaldo Cruz. 2011 Aug;106 Suppl 1:159-66.

11.

Inhibition of hypoxanthine-guanine phosphoribosyltransferase by acyclic nucleoside phosphonates: a new class of antimalarial therapeutics.

Keough DT, Hocková D, Holý A, Naesens LM, Skinner-Adams TS, Jersey Jd, Guddat LW.

J Med Chem. 2009 Jul 23;52(14):4391-9. doi: 10.1021/jm900267n.

PMID:
19527031
12.

Apical membrane antigen 1 as an anti-malarial drug target.

Macraild CA, Anders RF, Foley M, Norton RS.

Curr Top Med Chem. 2011;11(16):2039-47. Review.

PMID:
21619512
13.

Proteomic approaches to studying drug targets and resistance in Plasmodium.

Cooper RA, Carucci DJ.

Curr Drug Targets Infect Disord. 2004 Mar;4(1):41-51. Review.

PMID:
15032633
14.

Drug-resistant malaria in children and in travelers.

Longworth DL.

Pediatr Clin North Am. 1995 Jun;42(3):649-64. Review.

PMID:
7761145
15.

Chloroquine resistant malaria in children.

Memon IA, Kanth N, Murtaza G.

J Pak Med Assoc. 1998 Apr;48(4):98-100.

16.

In vivo responses to antimalarials by Plasmodium falciparum and Plasmodium vivax from isolated Gag Island off northwest Irian Jaya, Indonesia.

Fryauff DJ, Sumawinata I, Purnomo, Richie TL, Tjitra E, Bangs MJ, Kadir A, Ingkokusumo G.

Am J Trop Med Hyg. 1999 Apr;60(4):542-6.

17.

Genetic and biochemical aspects of drug resistance in malaria parasites.

Hayton K, Su XZ.

Curr Drug Targets Infect Disord. 2004 Mar;4(1):1-10. Review.

PMID:
15032630
18.

Acyclic phosph(on)ate inhibitors of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase.

Clinch K, Crump DR, Evans GB, Hazleton KZ, Mason JM, Schramm VL, Tyler PC.

Bioorg Med Chem. 2013 Sep 1;21(17):5629-46. doi: 10.1016/j.bmc.2013.02.016. Epub 2013 Mar 5.

19.

Purine and pyrimidine pathways as targets in Plasmodium falciparum.

Cassera MB, Zhang Y, Hazleton KZ, Schramm VL.

Curr Top Med Chem. 2011;11(16):2103-15. Review.

20.

Antimalarial drugs and drug targets specific to fatty acid metabolic pathway of Plasmodium falciparum.

Qidwai T, Khan F.

Chem Biol Drug Des. 2012 Aug;80(2):155-72. doi: 10.1111/j.1747-0285.2012.01389.x. Epub 2012 May 28. Review.

PMID:
22487082
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk